Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 183%
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Kodiak Sciences Stock Surges 156% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration. Continue Reading
Oncobiologics Q3 Earnings Call Highlights
Key Points Interested in Oncobiologics, Inc.? Here are five stocks we like better. FDA approval clears the way for LYTENAVA's U.S. launch later this year as the only FDA-approved ophthalmic bevacizumab formulation for wet AMD. Management i…
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago. These figures are adjusted for non…
Outlook Therapeutics slides after pricing $55M securities offering
Outlook Therapeutics (OTLK [https://seekingalpha.com/symbol/OTLK]) shares fell nearly 15% in premarket trading Thursday after the company priced a public offering of 55.6M shares and warrants for gross proceeds of about $55M. The combined…
Outlook Therapeutics Prices $55 Mln Offering To Support LYTENAVA Launch; Stock Down
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, priced a public offering of 55.56 million shares and accompanying warrants to purchase up to 55.56 million shares at a combined public offering price of $0.99 for…
OTLK Up More Than 300% in 3 Months: Here's What You Should Know
Shares of Outlook Therapeutics OTLK have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company's sole product, Lytenava, which is approved for the treatment of patien…
Earnings Week Ahead: SMCI, CSCO, JD, PLUG, and more
[Business Person Reviewing Quarterly Report During Meeting in Office Setting] The second full week of August features a diverse earnings slate spanning AI infrastructure, semiconductors, space technology, healthcare, financials, and consum…
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.32 per share a year ago. These figures are adjusted for non…
Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?
We expect Outlook Therapeutics OTLK to beat expectations when it reports third-quarter fiscal 2026 results later this month. In the last reported quarter, the company delivered a negative earnings surprise of 33.33%. The Zacks Consensus Es…
Twist Bioscience (TWST) Reports Q3 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items. Thi…
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.'s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizum…
Outlook Therapeutics Wins FDA Nod For LYTENAVA After Three Setbacks
(RTTNews) - Outlook Therapeutics (OTLK) announced that the FDA has approved LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of neovascular age-related macular degeneration (wet AMD). Wet…
Outlook gains approval for ophthalmic bevacizumab for wet AMD
[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * The US FDA has approved Ou…
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation Company Launches C…
Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict
(RTTNews) - Today's top gainers in the biotech space include NextCure, ahead of its planned merger with a private company that will create a newly branded public entity; Basel Medical, which recently regained Nasdaq compliance; and Outlook…
Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is one of the 10 High Growth Stocks Insiders Are Buying. On June 16, 2026, Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced that the U.S. Food and Drug Administration acknowledged receipt of the r…
Haleon (HLN) Partners with Microsoft (MSFT) to Advance Digital and AI Capabilities
Haleon (NYSE:HLN) is one of the best up and coming stocks to invest in right now. On June 1, Haleon announced a five-year collaboration with Microsoft (NASDAQ:MSFT) to scale its digital, data, and AI capabilities. This partnership aims to…
Biotech Stocks Facing FDA Decision In July 2026
(RTTNews) - July is here, and the FDA is set to announce decisions on therapies for conditions ranging from breast cancer and IgA nephropathy to multiple myeloma, ADHD, and wet AMD. Before turning our attention to the key FDA decisions exp…
Catalyst Watch: Micron earnings, Amazon Prime Day, and stress tests for major banks
[Panorama cityscape view of Aerial View of Downtown Manhattan at Sunrise, New York City, USA.] JK1991/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out.…
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
Shares of Outlook Therapeutics OTLK rallied 35.3% on Tuesday after the company announced that the FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, its investigational treatment for neovascular age-rel…
Outlook Therapeutics Prices $5 Million Registered Direct Offering
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) announced it has priced a $5.0 million registered direct offering of its common stock, structured at-the-market under Nasdaq rules. The company entered into a definitive agreement to sell 8,539…
Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest
(RTTNews) - In Thursday's list of gainers, we highlight SciSparc, which received the regulatory go-ahead to acquire a stake in a private Israeli technology company, Co-Diagnostics, which extended its rally for the third straight day, and T…
Outlook Therapeutics Wins FDA Appeal For NAMD Therapy; Stock Up
(RTTNews) - Outlook Therapeutics Inc. (OTLK) announced that the U.S. FDA has granted its appeal following completion of the Formal Dispute Resolution process for ONS-5010/LYTENAVA (bevacizumab-vikg). Its investigational therapy for neovasc…
Outlook Therapeutics Q2 Net Loss Narrows; Expects FDA Decision For LYTENAVA In May 2026
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, announced financial results for the second quarter of fiscal year 2026, ended March 31, 2026, and provided a corporate update. Company Profile Outlook Therapeutics…
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment o…
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it…
FDA Accepts Outlook Therapeutics' FDRR To Resolve ONS-5010/LYTENAVA Regulatory Issues; Stock Up
(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a clinical-stage biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration FDA has accepted its Formal Dispute Resolution Request or FDRR and has granted a meeting…
Outlook Therapeutics Hits 52-Week Low As It Launches Proposed Public Offering
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) announced that it has proposed a best-efforts public offering of its common stock and accompanying warrants, a move that comes as the company's shares hover at a fresh 52-week low. The offering…
Outlook Therapeutics Announces Proposed Public Offering
ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it…
Outlook Therapeutics Secures $18.4 Million Financing; Stock Up
(RTTNews) - Outlook Therapeutics, Inc. (OTLK) announced it has entered into a new $18.4 million non-convertible note financing and amended its existing convertible note agreements, bolstering its cash position as the company advances comme…
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an updat…
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026Additional European launches expected in 2026Type A meeting request submitted to the U.S. Food and Drug Administ…
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third complete response letter (CRL) in late December, rejecting OTLK’s biologics license application (BLA) resubmissio…
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.5% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Baidu, ASML, furniture stocks rise; Outlook Therapeutics sinks
Investing.com -- U.S. futures are trading higher with Nasdaq 100 Futures futures up as much as 1.1% in pre-market Friday. ASML (NASDAQ:ASML) are up 4.9% after Aletheia Capital double-upgraded the European-listed shares of the chip equipmen…